Pregnancy, Reproductive Factors, and Female Heart Failure Risk and Outcomes.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2024-06-01 Epub Date: 2024-03-20 DOI:10.1007/s11897-024-00657-x

Guillermo Moreno, Manuel Martínez-Sellés, María Jesús Vicente-Galán, Lourdes Vicent

{"title":"Pregnancy, Reproductive Factors, and Female Heart Failure Risk and Outcomes.","authors":"Guillermo Moreno, Manuel Martínez-Sellés, María Jesús Vicente-Galán, Lourdes Vicent","doi":"10.1007/s11897-024-00657-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this review is to provide an overview of recent evidence on female-specific risk factors related to reproductive status or pregnancy.Recent findings: Pregnancy-related factors, including hypertensive disorders and gestational diabetes, increase the risk of heart failure in women, while breastfeeding and hormone therapy may offer protection. Hypertensive disorders of pregnancy, gestational diabetes, polycystic ovarian syndrome, placental abruption, younger maternal age at first live birth, younger maternal age at last live birth, number of stillbirths, number of pregnancies, onset of menstruation before 12 years of age, shorter reproductive age, ovariectomy, and prolonged absence of ovarian hormones may increase the risk of heart failure in women. Conversely, breastfeeding status and hormone therapy (for menopause or contraception) may serve as protective factors, while fertility treatments have no discernible effect on the risk of heart failure.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"203-213"},"PeriodicalIF":3.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00657-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this review is to provide an overview of recent evidence on female-specific risk factors related to reproductive status or pregnancy.

Recent findings: Pregnancy-related factors, including hypertensive disorders and gestational diabetes, increase the risk of heart failure in women, while breastfeeding and hormone therapy may offer protection. Hypertensive disorders of pregnancy, gestational diabetes, polycystic ovarian syndrome, placental abruption, younger maternal age at first live birth, younger maternal age at last live birth, number of stillbirths, number of pregnancies, onset of menstruation before 12 years of age, shorter reproductive age, ovariectomy, and prolonged absence of ovarian hormones may increase the risk of heart failure in women. Conversely, breastfeeding status and hormone therapy (for menopause or contraception) may serve as protective factors, while fertility treatments have no discernible effect on the risk of heart failure.

查看原文本刊更多论文

妊娠、生殖因素与女性心力衰竭的风险和结果。

综述目的：本综述旨在概述与生殖状况或妊娠有关的女性特异性风险因素的最新证据：与妊娠有关的因素，包括高血压疾病和妊娠糖尿病，会增加女性心力衰竭的风险，而母乳喂养和激素治疗可能会提供保护。妊娠期高血压疾病、妊娠期糖尿病、多囊卵巢综合征、胎盘早剥、首次活产时产妇年龄较小、最后一次活产时产妇年龄较小、死胎数量、妊娠次数、12 岁前月经初潮、生育年龄较短、卵巢切除术和长期缺乏卵巢激素可能会增加女性心衰的风险。相反，母乳喂养状况和激素治疗（绝经或避孕）可能是保护因素，而生育治疗对心衰风险没有明显影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.